The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the ...

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the ...

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the ...

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

Beyfortus made $1.8 billion in sales last year, even though supplies were held back by now-resolved production constraints.

Infants will receive the product Beyfortus, described as a long-acting monoclonal antibody with protection that lasts a full RSV season, typically from November to April.

Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect their babies for the first six months after ...